Cytokines secreted from dendritic cells (DCs) play an important role in the regulation of T helper (Th) cell differentiation and activation into effector cells. Therefore, controlling cytokine secretion from DCs may potentially regulate Th differentiation/activation. DCs also induce de-novo generation of regulatory T cells (Treg) that modulate the immune response. In the current study we used the mixed leukocyte reaction (MLR) to investigate the effect of allospecific Treg on IL-12, TNFα and IL-6 secretion by DCs. Treg cells were found to markedly down-regulate IL-12 secretion from DCs following stimulation with TLR7/8 agonist. This down-regulation of IL-12 was neither due to a direct suppression of its production by the DCs nor a result of marked DC death. We found that IL-12 was rather actively consumed by Treg cells. IL-12 consumption was mediated by a subpopulation of IL-12Rβ2-expressing Treg cells and was dependent on MHC class-II expressed on dendritic cells. Furthermore, IL-12 consumption by Tregs increased their suppressive effect on T cell proliferation and Th1 activation. These results provide a new pathway of Th1 response regulation where IL-12 secreted by DCs is consumed by a sub-population of IL-12Rβ2-expressing Treg cells. Consumption of IL-12 by Tregs not only reduces the availability of IL-12 to Th effector cells but also enhances the Treg immunosuppressive effect. This DC-induced IL-12Rβ2-expressing Treg subpopulation may have a therapeutic advantage in suppressing Th1 mediated autoimmunity.
Introduction
T cell differentiation into effector Th cells in response to an antigen is stimulated by DCs together with cytokines. For example, for Th1 cell differentiation, DCs provide the IL-12 required by the Th cells [1] [2] [3] [4] [5] . The various types of Th cells provide resistance to different types of infection but also mediate unwanted reactions such as autoimmunity, allergy and transplant rejection [6] [7] [8] . Therefore, regulating cytokine secretion from DCs would be important in modulating Th cell activation and differentiation and subsequently to achieve remission in some of these pathological conditions. Naïve CD4+ cells can also be induced to become regulatory T cells (iTreg) upon stimulation with an antigen presented by DCs in the presence of TGFβ [9, 10] . The combined presence of TGFβ and all-trans-retinoic-acid (ATRA) enhances the induction of alloreactive Treg from the polyclonal CD4+ T cells [11] . These de-novo-generated iTreg exert substantial specificity in suppressing allogeneic DC both in culture and in a mouse model of graft vs. host disease [11] . Treg cells can inhibit T cell function by several mechanisms [12, 13] , some of which require direct Treg suppression of DCs. This suppression involves down-regulation of CD80 and CD86 expression on DCs [14, 15] and up-regulation of its indoleamine 2,3-dioxygenase (IDO) activity [16] . These effects of Treg on DCs are mediated by the co-inhibitory molecule CTLA-4, [16, 17] a major molecule with which Treg regulate antigen presenting cell (APC) function [18] , and by a possible effect of IL-10 secreted from Treg [19] . However, the direct effect of Treg in general and more specifically of iTreg on cytokine secretion by DCs is less well established.
The MLR system enables both the induction of Treg from the polyclonal repertoire of CD4+ T cell population and the evaluation of their specificity to the inducing allogeneic DCs [11] . In the present study we used the MLR system [11] to investigate whether allospecific polyclonal iTreg cells can regulate DC secretion of IL-12, TNFα and IL-6, as well as its mechanism and effect on the Th response.
Results and Discussion

DC-Induced Treg Cells Specifically Down-Regulate IL-12 Secreted from DCs by Its Consumption
To determine if iTreg cells reduce cytokine secretion by DCs, we first used Balb/c DCs to induce allospecific iTreg from C57Bl/6 (B6) Foxp3 -CD4+ cells as described previously { [11] , and S1 Fig}. The iTreg were then incubated with fresh Balb/c DCs for 24 hrs, after which TLR 7/8 ligand Thiazoloquinolone (CL075, 3M002) was added for an additional 24 hrs. CL075 induced IL-12 release from DCs, but this was completely blocked when iTreg were added ( Fig  1A) . In contrast, TNFα release was only mildly reduced by adding iTreg (up to 30%, S2 Fig) .
To test whether suppression of IL-12 production also occurred when iTreg were suppressing an immune response, we added the iTreg to Balb/c DC along with fresh B6 CD4+ cells. The MLR between B6 T cells and Balb/c DC produces a powerful immune response but does not detectably result in IL-12 release unless CL075 was added (Fig 1B) . The main source for IL-12 production and release into the medium was the DCs as expected ( S3 Fig right and left) . Addition of iTreg but not CD4+CD25-Foxp3-(DN) cells significantly down-regulated IL-12 secretion in a dose dependent manner (Fig 1B) . However, production of two other cytokines, TNFα in response to CL075 and IL-6 in response to LPS, was only slightly reduced (~30%) following the addition of iTreg ( S4 Fig right and left) . Thus, based on these results, one functional effect of iTreg is to specifically suppress DC by reducing the level of secreted IL-12 in response to a TLR7/8 agonist.
To evaluate the specificity of the suppressive function of iTreg on IL-12 secretion from DCs, we generated iTreg cells by co-culturing B6 CD4 + CD25 -Foxp3 -cells (double negative) with either allo Balb/c DCs or SJL DCs in the presence of TGF-β and ATRA. The sorted CD4 + CD25 + Foxp3 + cells (double positive), termed "iTreg anti Balb/c" (when induced with specifically suppress an MLR induced by either Balb/c or SJL DCs [11] . Here we found that simultaneously with suppression of T cell proliferation in the context of the MLR (data not shown), the iTreg also down-regulated CL075-induced IL-12 secretion from DCs specifically. These "iTreg anti Balb/c" cells down regulated CL075-induced IL-12 secretion from Balb/c DCs more effectively than "iTreg anti SJL", and vice versa for IL-12 secretion from SJL DCs. (Fig 1C left and right, respectively) . Specificity was further evidenced in the finding that "iTreg anti Balb/c" significantly down-regulated the CL075-induced IL-12 secretion from Balb/c DCs, but did not affect IL-12 secretion from B6 DCs (Fig 1C, S5 Fig) . On the other hand, when added to F1 (Balb/c X B6) DCs, "iTreg anti Balb/c" significantly down-regulated CL075-induced IL-12 secretion in the same manner as it affected Balb/c (Fig 1C, S5 Fig) . We conclude that iTreg selected on allogeneic DC of one type, specifically suppress IL-12 from the same type of DCs, in the presence of alloreactive T cells.
To understand more about the mechanism for iTreg suppression of IL-12 release from DCs, we tested blocking antibodies to several components that are required for different aspects of iTreg formation and function [12, 15, 17] . The antibodies were added to co-cultures of Balb/c DC, anti Balb/c specific iTreg, and B6 MLR responsive T cells, along with CL075. Anti-MHC class II mAbs (N22) abrogated the iTreg effect on IL-12 production, whereas the control hamster Ig isotype did not ( S6 Fig upper panel) . In contrast, blockade of TGFβ (S6 Fig, right lower panel) and blockade of CTLA4 (S6 Fig, left lower panel) or LFA-1 (data not shown), did not restore IL-12 release into the culture medium. Thus, the capacity of iTreg to block IL-12 release from DC is dependent on MHC II.
To assess if the down-regulation of IL-12 reflects increased dendritic cell death, as recently reported in an in vivo model [20] , we stained cultures of DCs and T cells incubated with or without iTreg for viability. As shown in S7A Fig, co -incubation with iTreg decreased the number of live DCs by 30%. This reduction may explain the modest decrease in TNFα and IL-6 that we observed (S4 Fig), but seems unlikely to explain the almost 10 fold reduction in IL-12 secreted by DCs (Fig 1B) .
To determine if the reduction in IL-12 measured from DC culture was due to suppression of its synthesis, we looked directly at IL-12 transcription and intracellular IL-12. S7B and S7C Fig demonstrate minimal changes in levels of IL-12 p40 mRNA and protein in the DCs. Thus, to our surprise, the ability of iTreg to suppress IL-12 release is not likely due to the toxicity or reduced IL-12 synthesis by DCs per se.
Given the above findings we searched for a new IL-12 control mechanism, whereby IL-12 would be consumed as a result of DC-iTreg interaction. We first added 800 pg/ml IL-12 to a co-culture of DCs with either naïve CD4+ cells or iTreg in the absence of CL075 stimulation. This is the concentration reliably secreted by DCs in our culture system stimulated by CL075 (Fig 1B) . Addition of this amount of IL-12 to co-cultures of DCs and CD4+ T cells was followed by a 3-fold reduction in IL-12 levels (201 pg/ml and 617 pg/ml with or without a co-culture of DCs and CD4+ T cells, respectively). However, addition of IL-12 to a co-culture of DCs and iTreg cells resulted in a 12-fold reduction in IL-12 levels (50 pg/ml and 617 pg/ml with or without a co-culture of DCs and iTreg cells, respectively). This 12-fold reduction required the presence of both DCs and iTreg cells (Fig 1D) , while each cell type alone resulted in either mild or no reduction in the level of IL-12 (450 pg/ml and 647 pg/ml, respectively). To further support the notion of IL-12 consumption by iTreg cells we wanted to evaluate the time course of removal of the added IL-12 from the media. The time required for IL-12 consumption was relatively short, as a two fold reduction was achieved within 0.5-3 hrs of co-incubation of DCs and iTreg cells in the IL-12 added media, and a maximum reduction of 10-12 fold after 12-24 hrs (Fig 1E) . A rough estimate of IL-12 consumed per cell was 0.0005 pg IL-12 per cell in 12 hrs orother hand, iTreg cells alone or co-incubated with DCs did not reduce TNFα when added to the medium (S8 Fig). The fact that the IL-12 level continues gradually and consistently to drop over time to almost complete removal (Fig 1E) , rules out the possibility of saturation of IL-12 binding, in which we would expect a "plateau effect" after an initial steep non-gradual decline. However, the continued drop in IL-12 concentration support a possible mechanism of receptor uptake and recycle.
IL-12 Consumption Is Mediated by Treg IL-12Rβ2 and Dependent on DC MHC-Class-II
To test the possibility that IL-12 consumption was mediated by binding to IL-12R on the iTreg cells, we compared iTreg and naïve CD4+ cells for IL-12R β1 and β2 mRNA expression by RT-PCR. As shown in Fig 2A, iTreg cells sorted and analyzed immediately after their induction had higher levels of IL-12Rβ1 and even more IL-12Rβ2 compared to naïve CD4+ cells. To pinpoint the IL-12R expressing cells, we sorted iTreg that were co-cultured overnight either alone or with DCs, and compared their IL-12R expression to that of iTreg immediately after their induction. When iTreg were incubated alone overnight, expression of mRNA was greatly reduced for both IL-12R subunits, whereas iTreg cultured with DCs retained IL-12R mRNA (Fig 2B) . To prove that IL-12Rβ2 was responsible for IL-12 consumption, we compared iTreg from IL-12Rβ2 KO mice (Foxp3   -IRES -RFP (FIR) knock-in crossed with IL-12Rβ2 KO) to WTiTreg. Indeed, the IL-12Rβ2 KO-iTreg were unable to consume IL-12 ( Fig 2C) whereas DCs from IL-12Rβ2 KO mice incubated with WT iTreg were fully capable of inducing iTreg to consume IL-12 (Fig 2D) , ruling out the possibility that IL-12 was consumed by DCs.
To verify whether IL-12 consumption was dependent on an interaction with MHC class-II, WT iTreg were incubated with DCs from MHC-class-II-KO mice. Lack of MHC-II on DCs abrogated the consumption of IL-12 achieved by iTreg incubated with WT-DCs (Fig 2E) . Taken together, these results demonstrate that MHC-II expression on DCs and IL-12Rβ2 expression on iTreg are essential for the IL-12 consumption mechanism by iTreg.
We next tested if DCs can induce naturally occurring Treg (nTreg) to consume IL-12. To this end, we added IL-12 to a co-culture of Balb/c DCs with either freshly isolated CD4 + CD25 + Foxp3 + nTreg, or nTreg that were sorted after activation and expansion with allogeneic DCs in an MLR system as described [11] . We found that during the MLR, DC-activated but not freshly isolated nTreg consumed IL-12 ( Fig 2F) , and much like DC-induced iTreg the nTreg also up-regulated IL-12Rβ2 (Fig 2G) .
IL-12Rβ2 Expressed on Authentic Treg Contribute to the Control of Th1 Response by Effector T Cells while Mediating IFNγ Secretion in a Stat4 Dependent Manner
To determine the importance of IL-12 consumption on the immune response, we added IL-12 (1000 pg/ml) to cultures of allo DCs (Balb/c) and CD4+ T cells (B6). In the absence of IL-12, iTreg suppressed the MLR in a dose dependent manner (S9A Fig) . Since IL-12 was shown to increase T cell proliferation [21, 22] , we expected a reduced suppression of pre-activated/effector T cell proliferation by iTreg in the presence of IL-12. However, the addition of IL-12 surprisingly enhanced the inhibitory effect of the iTreg (S9A Fig upper and lower panel) . Further, this enhanced suppressive effect of iTreg in the presence of IL-12 was IL-12Rβ2 dependent. Indeed, WT iTreg suppressed T cell proliferation (S9B Fig) and IFNγ secretion (Fig 3A) from effector CD4+ cells several fold greater (2-3 and 3.5-5, respectively) than IL-12Rβ2 KO Treg. Moreover, the suppressive effect of WT iTreg (IL-12Rβ2 expressing) in the presence of IL-12 on the total number of IFNγ effector CD4+ secreting cells was 2-fold greater than the effect on (Fig 3A middle) versus~5-fold (S9B Fig middle) reduction, respectively, compared to MLR with effector CD4+ cells]. These results support a direct effect of Treg on effector Th1 response and IFNγ secretion beyond and possibly independent of the suppression of effector CD4+ proliferation. Together, these results may suggest that IL-12, a cytokine with effector immuno-stimulatory properties, gains suppressive function in the presence of IL12Rβ2-expressing iTreg. Our results may also explain cases in which single-nucleotide polymorphisms (SNPs) in IL-12, IL-12Rβ2, and Stat-4 were shown to increase the risk for diseases such as primary biliary cirrhosis [23] , in which Treg, and IL-12 are part of the pathogenesis. This may raise the possibility that the presence of the same SNPs on IL-12Rβ2 on iTreg abrogate their suppressive function.
IL-12 addition to a culture of nTreg cells was shown to induce IFNγ secretion through an unclear pathway [24, 25] . To verify that iTreg (induced with DCs in MLR) can secrete IFNγ, and to explore whether IFNγ secretion by iTreg is mediated via IL-12R expression, we studied the stimulatory effect of this receptor on cytokine secretion by iTreg. As was shown recently with nTreg [26] , here we demonstrate that addition of IL-12 to a culture of DCs and allospecific iTreg, induced marked up-regulation in IFNγ secretion from WT iTreg but not from IL-12Rβ2 KO iTreg cells (S10 Fig). Stat4 and T-bet act independently and synergistically to drive expression of the signature inflammatory cytokine IFN-γ [27, 28] . While it was demonstrated that Tbet+ nTreg undergo abortive Th1 cell differentiation due to the impaired expression of IL-12 receptor β2 [29] , here we demonstrate that the IFNγ secretion from iTreg was dependent on the transcription factor Stat-4 ( Fig 3B) which resides downstream of the IL-12R signaling pathway.
At this point we wanted to verify that the IL-12Rβ2-expressing cells are authentic Tregs and not ex-Foxp3 effector T cells [30] . In the absence of a reliable antibody against IL-12Rβ2, a culture of WT iTreg cells incubated with DCs, were sorted for CD4 + CD25 + Foxp3 + (RFP + ) single cells. By analyzing single cells for the concomitant expression of IL-12Rβ2 and Foxp3 mRNA, we could define a relatively abundant subpopulation (20-25%) of IL-12Rβ2 expressing Foxp3 + iTreg cells in WT mice (Fig 3C) .
Recent studies have shown that Foxp3+ Treg cells can functionally differentiate to acquire the ability to specifically control Th1, Th2 or Th17 type inflammatory responses of certain T helper types by modifying their expression of related transcription factors [31] [32] [33] . For example, Treg that acquired T-bet expression have been shown to control Th1 responses, though by a yet an unknown mechanism [31] . Here we show that a subpopulation of iTreg cells acquire the expression of IL-12R thereby contributing to the regulation of Th1 responses. Interestingly, this subpopulation of Treg cells uses the same receptor as effector Th1 cells in order to suppress Th1 responses. Simultaneously, the effector Th1-suppressive iTreg secrete IFNγ (in a Stat4 dependent manner), a cytokine, that when secreted from Treg, was shown recently to be suppressive in the context of graft versus host disease (GVHD) and transplant rejection [26, 34] . More specifically, Koenecke et al [26] have shown that only IFNγ-expressing and not IFNγ-deficient Treg could suppress GVHD. Taken together, IFNγ produced by iTreg is dependent on the IL-12/IL-12Rβ2/Stat4 pathway, and may further add to the suppression achieved by the IL-12Rβb2. In summary, we describe here a new pathway whereby DCs induce the expression of IL-12R on a subpopulation of Treg cells, in an MHC class II dependent manner. This novel mechanism contributes to the regulation of Th1 effector response by iTreg through the consumption of IL-12, which in this milieu becomes a cytokine with an immunosuppressive outcome. These DC-induced IL-12Rβ2-expressing Treg cells may have a significant therapeutic advantage in Th1 mediated autoimmunity. +(GFP+). Mice housing and husbandary was in Rockefeller University animal fascility, with regular diet and caging. The study was approaved by institutional animal care and use committee of the Rockefeller University, and we followed its guidelines. All experiment were done exvivo after euthanesia with CO2 according to the guidelines of our institute.
Material and Methods
Antibodies and Reagents
All following conjugated Abs are from BD:APC conjugated anti-mouse CD25, -CD4, -CD45.1, -CD11c, -IL-12p70; Alexa Fluor 700-conjugated anti-CD3, -CD4, and -CD11c; PE-conjugated anti-CD3, -CD19, and -CD49b; FITC-conjugated anti-CD3, -CD19, -CD49b, and isotype control; biotin anti-CD4, -CD8, -DX5, -B220, -CD3, -CD11b, -Ly-6G, and -Ter119; and purified anti-CD16/CD32 (2.4G2). CD11c and streptavidin beads (SA) from Miltenyi Biotec; CFSE, live dead fixable aqua, CL075, and LPS from Invitrogen; ATRA from Sigma-Aldrich; hTGF-β1, anti-mouse TGF-β (1D11), anti-CTLA4, and Ig isotype control from R&D Systems.
T Cells and DCs
Non-CD4 + lymph node and spleen T cells were removed by MACS beads (Miltenyi Biotec)
after coating with biotin anti-CD8α, DX5, B220, CD3, CD11b, Ly-6G, and Ter119. Cells were further purified with a FACSAria 2 sorter (BD) to >97%. Spleen CD11c + DCs were partially enriched with anti-CD11c beads (Miltenyi Biotec) and, where indicated, purified with a FACSAria 2 (BD) cell sorter as CD11c high CD19 − CD3 − DX5 − DCs (>95%). 
De Novo In Vitro Induction of T Reg Cells in the Allo-MLR
RTPCR for IL-12Rβ1, β2 and IL-12b
We used the Qiagen kit for RNA isolation from sorted Treg or DCs. SuperScript1 Reverse Transcriptase (Invitrogen) was used synthesize cDNA, from which IL-12Rβ1, β2 and IL-12b were amplified with PCR. An agarose gel electrophoresis of the PCR products was performed.
Single Cell Sort and Analysis
CD4+CD25+Foxp3+(RFP+) cells were sorted from a co-culture of WT iTreg and allo-DCs into 96-well PCR plates (Eppendorf) containing 4μl/well of ice-cold 0.5× PBS supplemented with 10 mM DTT, 8U RNAsin (Promega), and 3U RNAse Inhibitor (5Prime). cDNA was synthesized as described [36] , and nested PCR for IL-12Rβ2 and Foxp3 cDNA was performed. Statistical data were analyzed using Student's t test.
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